Author： Snowden M.M. Grove R.I.
Publisher： Informa Healthcare
ISSN： 1354-3776
Source： Expert Opinion on Therapeutic Patents, Vol.8, Iss.5, 1998-05, pp. : 509-520
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
The advent of gene therapy techniques has made it possible to intervene in cardiovascular diseases by transferring an appropriate therapeutic gene to the relevant cells in humans. A number of preclinical efforts have begun to culminate in clinical studies for life threatening conditions like hypercholesterolaemia and ischaemic vascular disease. Other cardiovascular indications are under investigation, with late stage preclinical studies focusing on restenosis, transplant atherosclerosis and rejection, and various lipoprotein abnormalities. Several recent reviews have outlined the issues surrounding gene therapy in general [1,2]. This review will discuss gene transfer approaches designed specifically to treat diseases of the cardiovascular system, and relevant patents and patent applications.
Related content
Gene therapy for cardiovascular diseases
Expert Opinion on Therapeutic Patents, Vol. 10, Iss. 9, 2000-09 ,pp. :
Access to resources
Recommend
Gene Therapy for Cardiovascular Diseases
Current Pharmaceutical Design, Vol. 10, Iss. 4, 2004-02 ,pp. :
Gene Therapy in Cardiovascular Diseases
Current Gene Therapy, Vol. 2, Iss. 4, 2002-12 ,pp. :
Gene Therapy Approaches for Cardiovascular Diseases
Current Gene Therapy, Vol. 4, Iss. 2, 2004-06 ,pp. :